...
首页> 外文期刊>International Journal of Nanomedicine >Filter-Membrane-Based Ultrafiltration Coupled with Surface-Enhanced Raman Spectroscopy for Potential Differentiation of Benign and Malignant Thyroid Tumors from Blood Plasma
【24h】

Filter-Membrane-Based Ultrafiltration Coupled with Surface-Enhanced Raman Spectroscopy for Potential Differentiation of Benign and Malignant Thyroid Tumors from Blood Plasma

机译:基于过滤膜的超滤,与表面增强拉曼光谱耦合,用于血液血浆的良性和恶性甲状腺肿瘤的潜在分化

获取原文
           

摘要

Objective: The objective of this study is to evaluate the performance and feasibility of surface-enhanced Raman spectroscopy coupled with a filter membrane and advanced multivariate data analysis on identifying and differentiating benign and malignant thyroid tumors from blood plasma. Patients and Methods: We proposed a membrane filter SERS technology for the differentiation between benign thyroid tumor and thyroid cancer. That is to say, by using filter membranes with optimal pore size, the blood plasma samples from thyroid tumor patients were pretreated with the macromolecular proteins being filtered out prior to SERS measurement. The SERS spectra of blood plasma ultrafiltrate obtained using filter membranes from 102 patients with thyroid tumors (70 thyroid cancers and 32 benign thyroid tumors) were then analyzed and compared. Two multivariate statistical analyses, principal component analysis-linear discriminate analysis (PCA-LDA) and Lasso-partial least squares-discriminant analysis (Lasso-PLS-DA), were performed on the SERS spectral data after background subtraction and normalization, as well as the first derivative processing, to analyze and compare the differential diagnosis of benign thyroid tumors and thyroid cancer. Results: SERS measurements were performed in blood plasma acquired from a total of 102 thyroid tumor patients (benign thyroid tumor N=32; thyroid cancer N=70). By using filter membranes, the macromolecular proteins in blood plasma were effectively filtered out to yield high-quality SERS spectra. 84.3% discrimination accuracy between benign and malignant thyroid tumor was achieved using PCA-LDA method, while Lasso-PLS-DA yields a discrimination accuracy of 90.2%. Conclusion: Our results demonstrate that SERS spectroscopy, coupled with ultrafiltration and multivariate analysis has the potential of providing a non-invasive, rapid, and objective detection and differentiation of benign and malignant thyroid tumors.
机译:目的:本研究的目的是评估表面增强拉曼光谱的性能和可行性,耦合滤膜和高级多元数据分析,用于识别和区分血液血浆的良性和恶性甲状腺肿瘤。患者和方法:我们提出了一种膜过滤器SERS技术,用于良性甲状腺肿瘤和甲状腺癌之间的差异化。也就是说,通过使用具有最佳孔径的过滤膜,甲状腺肿瘤患者的血液血浆样品用在SERs测量之前被过滤的大分子蛋白质进行预处理。然后使用来自102例甲状腺肿瘤(70甲状癌和32良性甲状腺肿瘤)使用过滤膜获得的血液血浆超滤液的SERS光谱,并进行比较。两个多变量统计分析,主成分分析 - 线性区分分析(PCA-LDA)和租赁部分最小二乘判别分析(LASSO-PLS-DA)在背景减法和归一化之后进行SERS光谱数据,以及第一种衍生物处理,分析和比较良性甲状腺肿瘤和甲状腺癌的差异诊断。结果:SERS测量在血浆中进行的总共102例甲状腺肿瘤患者(良性甲状腺肿瘤N = 32;甲状腺癌N = 70)。通过使用过滤膜,有效地滤出血浆中的大分子蛋白以产生高质量的SERS光谱。使用PCA-LDA方法实现了良性和恶性甲状腺肿瘤之间的84.3%的歧视精度,而Lasso-PLS-DA产生90.2%的歧视精度。结论:我们的结果表明,SERS光谱,与超滤和多变量分析相结合,具有提供非侵入性,快速,客观的良性和恶性甲状腺肿瘤的无侵入性,快速和客观的探测和分化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号